At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 27 enrolled
Drug / intervention
telmisartan+amlodipine fixed dose combinationdrug
Likely dose
telmisartan+amlodipine fixed dose combination 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Study to Evaluate the Antihypertensive Effects of the Fixed-dose Combination of Telmisartan 80 mg and Amlodipine 5 mg (T80/A5) Given Once Daily by 24 h ABPM in Patients With Moderate to Severe Hypertension
In Brief
A Phase 3 clinical trial evaluating telmisartan+amlodipine fixed dose combination for Hypertension. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The primary objectives of this trial is to evaluate the changes from baseline (Visit 2) in the 24-hour Ambulatory Blood Pressure Monitoring mean (relative to dose time) for diastolic blood pressure and systolic blood pressure after 8 weeks of treatment with Telmisartan 80mg/Amlodipine 5mg in patients with moderate to severe hypertension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartNov 2010
Primary CompletionJul 2011
TodayJul 2026
First PostedSep 17, 2010
Enrollment StartNov 1, 2010
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.8 years ago
Interventions
telmisartan+amlodipine fixed dose combinationdrug
after 2 weeks placebo wash-out, patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.